Sustained Release Ocular Drug Delivery Systems: What Lies Ahead?

Published: April 2014

Roots Analysis has announced the addition of “Sustained Release Ocular Drug Delivery Systems Market, 2014-2024” report to their offering. The report provides an extensive study of this field, focusing on commercial implants and those under development, their applications and the likely mid-long term evolution. Venture capital firms have shown a lot of interest in this space. Numerous rounds of funding, totalling ~USD 100 million, were completed in 2013.

Raghav Goyal, the principal analyst, said, “Currently only three sustained release drug delivery systems are commercially available. A number of products are in preclinical and clinical stages of development. It is widely anticipated that this market has a huge potential; we certainly expect it to witness strong growth in near future”.

In fact, one of the key objectives of this report is to understand the future state of the industry. The report forecasts that the overall market is likely to be more than USD 1 billion in the coming decade; significant upside could be achieved by the successful approval of implants to deliver biologics. This forecast is based on insights gathered from secondary research and interviews of a number of companies, such as, Mati Therapeutics and On Demand Therapeutics.

Goyal further stated, “Diabetic Macular Edema (DME) will provide the much needed boost in the short-term. The potential in the market is huge with a high target population, which is growing significantly due to the rise in cases of diabetes. In the mid-long term, growth will be driven by launch of sustained release systems for glaucoma and AMD. At least three companies have sustained release systems delivering prostaglandin analogues in phase II development and one in phase I/II for the treatment of glaucoma and ocular hypertension.”


Who will benefit from this report?

The research is targeted towards big and small pharma companies working in the field of ocular drug delivery systems. In particular, you could benefit if you are an:

  • Investor
  • CXO level decision maker
  • R&D manager
  • Business Intelligence / Scientific analyst
  • Finance manager
  • Strategy head

For additional details and/or to request sample pages, please visit Alternatively, you can email at sales@rootsanalysis.comfor further details.

The company has also recently worked on studies related to Dry Eye Syndrome and AMD. Details can be found at


About Roots Analysis

Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry